ATLANTA, Oct. 30 CryoLife, Inc. (NYSE: CRY), abiomaterials, medical device and tissue processing company, announced todaythat Scott B. Capps has been named vice president, clinical research,effective October 29, 2007. Mr. Capps has served as vice president andgeneral manager of CryoLife Europa, Ltd., based in the U.K., since February2005.
Mr. Capps joined CryoLife in 1995 and has held several positions with theCompany including project director for heart valves, director of clinicalresearch and director of European clinical affairs. He is a graduate of theGeorgia Institute of Technology and holds a Master's degree in bioengineeringfrom Clemson University.
In a related move, David N. Hollinworth, Ph.D., has joined the company asvice president and general manager of CryoLife Europa, Ltd., effective October29, 2007. Previously, Dr. Hollinworth held various management positionsincluding chief executive officer of Chameleon Biosurfaces, Europeancardiology marketing manager of Siemens Medical and European marketdevelopment manager in cardiology at Medtronic. Dr. Hollinworth holds a Ph.D.in biochemistry from The University of Bristol and an M.B.A. from the LondonBusiness School.
"Scott did a terrific job for CryoLife Europa, and we are very excitedabout tapping into the expertise he gained while there. His experiences withCryoLife, both in Europe and stateside, make him well qualified to lead ourclinical operations here," said Steven G. Anderson, president and CEO ofCryoLife, Inc. "I am also very pleased to welcome Dr. Hollinworth as generalmanager of CryoLife Europa. His extensive background in the marketing of newtechnologies and products will be of great assistance in the introduction ofour new product pipeline in the years ahead."
About CryoLife, Inc.
Founded in 1984, CryoLife, Inc. is a leader in the processing anddistribution of implantable living human tissues for use in cardiac andvascular surgeries throughout the United States and Canada. The Company'sBioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures andstaples for use in adult patients in open surgical repair of large vessels.BioGlue is also CE marked in the European Community and approved in Canada andAustralia for use in soft tissue repair. The Company also distributes theCryoLife-O'Brien(R) stentless porcine heart valve, which is CE marked fordistribution within the European Community.For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com CryoLife Media Contacts: D. Ashley Lee Executive Vice President, Chief Operating Officer and Chief Financial Officer CryoLife, Inc. Phone: 770-419-3355 Katie Brazel Fleishman-Hillard Phone: 404-739-0150
SOURCE CryoLife, Inc.